Secondary Hypotheses 3. Greater than 50% of treatment responders to rTMS will continue to experience clinical benefits from rTMS, as indexed by HAMD scores remaining within 25% of the HAMD score achieved at the end of the acute treatment phase during the 6 months of post acute treatment follow up.